IGC Pharma Expands Phase 2 Trial Of IGC-AD1 To Include The University Of Puerto Rico
Portfolio Pulse from Benzinga Newsdesk
IGC Pharma has expanded its Phase 2 trial of IGC-AD1 to include the University of Puerto Rico. The first patient dosing commenced on May 19, 2023, and trial enrollment completion and top line data are expected in early 2024.
August 04, 2023 | 11:11 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
IGC Pharma's expansion of its Phase 2 trial of IGC-AD1 to include the University of Puerto Rico could potentially accelerate the trial process and bring the drug closer to market.
The expansion of the trial to include the University of Puerto Rico could potentially increase the diversity of the trial population and accelerate the trial process. This could bring the drug closer to market, which could have a positive impact on IGC's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100